Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss
May 11, 2015 7:52 AM EDTCantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) following a 1Q15 EPS miss. JAZZ reported in-line revenue of $309M, but missed the adjusted diluted EPS with $1.99 (vs. $2.14 estimates). Cantor Fitzgerald said that they... More
Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss
May 8, 2015 8:46 AM EDTGuggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This follows an EPS miss from JAZZ in 1Q15. JAZZ reported 1Q15 adjusted diluted EPS of $1.99. This came in $0.15 lower than consensus and $0.18 lower than Guggenheim estimated. Guggenheim believes that... More
